• LAST PRICE
    0.0850
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0660/ 100
  • Ask / Lots
    0.0998/ 199
  • Open / Previous Close
    --- / 0.0850
  • Day Range
    ---
  • 52 Week Range
    Low 0.0336
    High 0.1722
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesINTI
Inhibitor Therapeutics Inc
14.6M
-4.8x
---
United StatesCING
Cingulate Inc
14.5M
0.0x
---
United StatesIMUC
Eom Pharmaceutical Holdings Inc
15.2M
-3.1x
---
United StatesINAB
IN8BIO, Inc.
15.5M
-0.4x
---
United StatesKZIA
Kazia Therapeutics Ltd
21.0M
-0.8x
---
United StatesNRXP
NRX Pharmaceuticals Inc
13.7M
-0.8x
---
As of 2024-11-12

Company Information

Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

Contact Information

Headquarters
4830 W. Kennedy Blvd., Suite 600TAMPA, FL, United States 33609
Phone
813-766-2462
Fax
813-527-0500

Executives

Executive Chairman of the Board, Chief Executive Officer
Francis O'Donnell
Chief Financial Officer, Treasurer, Secretary
James Mcnulty
Director
Ronald Osman
Independent Director
Michael Jerman
Independent Director
Samuel Sears

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.6M
Revenue (TTM)
$0.00
Shares Outstanding
172.3M
Inhibitor Therapeutics Inc does not pay a dividend.
Beta
-0.59
EPS
$-0.02
Book Value
$0.03
P/E Ratio
-4.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.